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Barrett’s oesophagus (BE) is a pre-malignant condition in which
progression from metaplasia to low-grade dysplasia and high-
grade dysplasia could lead to invasive adenocarcinoma of the
oesophagus (AC) (Hameeteman et al, 1989; van der Burgh et al,
1996; Drewitz et al, 1997). High-grade dysplasia is often regarded
as an indication for oesophagectomy (Clark et al, 1996; Edwards
et al, 1996; Cameron and Carpenter, 1997). A possible alternative,
which is less mutilating and also applicable in patients with a high
surgical risk, is 5-aminolaevulinic acid-induced photodynamic
therapy (ALA-PDT).
Two relevant clinical studies have been performed, in which
patients with high-grade dysplasia or early cancer in BE received
an oral dose of ALA (60 mg kg–1), followed by photoactivation
4–6 h later (Barr et al, 1996; Gossner et al, 1998). Both high-grade
dysplasia and early cancer were eradicated allowing regeneration
of squamous epithelium without scarring or stricture formation.
However, the presence of islands of columnar cells remaining
beneath regenerating squamous epithelium created the concern
that superficial healing could mask underlying dysplasia. These
results suggest that ALA-PDT needs to be improved.
Haem biosynthesis, an essential process in every cell, is the
basis of ALA-PDT (Figure 1). ALA is the first intermediate, and
two molecules of ALA are converted to porphobilinogen (PBG)
which is metabolized to porphyrinogen intermediates by porpho-
bilinogen deaminase (PBG-D). The last step of haem biosynthesis
is the insertion of iron into PPIX by ferrochelatase (FC). Normally,
haem synthesis is regulated by feedback inhibition of the enzyme
ALA synthase. Exogenous ALA bypasses this feedback inhibition
and the activities of PBG-D and FC and the intracellular iron pool
become rate-limiting factors. As a result porphyrins, predomi-
nantly PPIX, will accumulate (Bishop and Desnick, 1982;
Kennedy and Pottier, 1992). Previously, we observed an imbal-
ance between the activities of PBG-D and FC in BE and AC
(Hinnen et al, 1998). The ratio between PBG-D and FC activities,
normalized for squamous epithelium, was found to be signifi-
cantly higher in BE and AC. In that study, we suggested that this
ratio, which we have called the PDT power index, might be a
useful parameter for predicting the accumulation of PPIX in
tissues after the administration of ALA.
In this study, we examined the relation between the PDT power
index and the intracellular concentration of PPIX in tissues of
patients with BE and AC at approximately 6 h after ALA ingestion
(60 mg kg–1) as this is the clinically most frequently used time
interval. We determined the intracellular concentrations of ALA
and other haem intermediates by biochemical extraction methods
rather than fluorescence microscopy as used by others (Regula et
al, 1995; Barr et al, 1996). In addition, plasma pharmacokinetics of
ALA and porphyrins were studied and side-effects were monitored.
MATERIALS AND METHODS
Patients
In total 10 patients (two women and eight men; age 44–81 years;
mean 65 years) gave their written informed consent to participate
in this study, which was approved by the Medical Ethical
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Committee of the University Hospital Rotterdam. Nine patients
with histologically proven AC in BE and one patient with high-
grade dysplasia in BE underwent an oesophageal resection with a
gastric tube interposition. One patient was excluded from analysis
because the tissue samples taken from BE were contaminated with
AC as samples were taken at the border between BE and AC.
Study design
Biopsy samples (pre-5-aminolaevulinic acid administration)
Apart from one patient, all patients underwent an endoscopy with
biopsies taken from BE, AG normal gastric cardia mucosa (GC)
and normal squamous epithelium (SQ). Biopsies were embedded
in formalin, sectioned, and stained with haematoxylin and eosin.
The grade of tumour differentiation and the grade of dysplasia in
Barrett’s mucosa were described according to Haggitt (Haggitt,
1994). In addition, adjacent biopsies were kept at –70°C until the
activities of PBG-D and FC and porphyrin concentrations were
determined (Hinnen et al, 1998).
5-Aminolaevulinic acid administration
Six hours before the oesophageal resection, ALA (Fluka, Buchs,
Switzerland, 60 mg kg–1) was dissolved in orange juice (10 ml, at
room temperature) and given to the patient. Following this, all
patients drank an additional 30 ml of water.
Photodegradation of porphyrins and photosensitization tissue-
damage during exposure to the operating lights was prevented by
covering the tissues not in the immediate operating field with
gauzes and shielding the operating lights with acrylate yellow
filters (Wientjes BV, Roden, The Netherlands), which eliminate
nearly all UV and blue light below a wavelength of about 520 nm
(Hinnen et al, 2000a). For 48 h after the administration of ALA,
patients were kept in subdued light. Side-effects were monitored
by questionaires and physical examination.
Blood samples
Venous blood samples were collected prior to and at 1, 3, 6, 9, 12,
24 and 48 h after the administration of ALA. Whole blood was
collected in tubes wrapped in aluminum foil to prevent photocon-
version and photodamage, and kept on ice. The blood samples were
centrifuged at 1300 g for 10 min, then the plasma was removed,
protected from light and stored at –70°C until the determinations of
ALA, porphobilinogen (PBG), uroporphyrin (URO) and PPIX. In
addition, samples were collected for routine biochemistry (urea,
creatinine, sodium, potassium, albumin, alkaline phosphatase,
bilirubin, aspartate aminotransferase (ASAT) and alanine amino-
transferase (ALAT)).
Tissue samples (post-5-aminolaevulinic acid administration)
Immediately after the oesophageal resection, tissue samples were
taken from BE, AC, SQ and GC for histological examination.
Adjacent tissue samples were kept at –70°C until the determina-
tions of ALA, PBG, URO and PPIX. It was not always possible to
take tissue samples at exactly 6 h after the administration of ALA
as in some patients the start of the operation was delayed by the
prolonged anaesthetic preparations and in others the anaesthetic
procedure was complicated by hypotension (see Results).
However six of nine patients were sampled at about 6 ± 0.5 h.
Laboratory assays
Chemicals
PPIX disodium salt, Zinc-PPIX and PBG were obtained from
Porphyrin Products (Logan, UT, USA). Coproporphyrin, URO and
Triton X-100 were obtained from Sigma Chemical Co. (St. Louis,
MO, USA). Tris-HCL was obtained from Boehringer Mannheim
(Mannheim, Germany) and all other chemicals were obtained from
Merck (Darmstadt, Germany).
Porphobilinogen deaminase and ferrochelatase assays
Tissue samples, kept on ice, were homogenized in water (1:5,
wt/wt) using a Potter Elvehjem homogenizer (Kontess Glass Co.,
Vineland, NJ, USA). PBG-D and FC activities as well as the PDT
power index – the ratio between PBG-D and FC in BE and AC in
comparison with SQ – were determined as described previously
(Hinnen et al, 1998). Data were expressed as pmol per mg protein
per hour. Protein was determined according to the method of
Lowry et al (1951).
Determinations of 5-aminolaevulinic acid, porphobilinogen,
uroporphyrin and protoporphyrin IX in plasma and tissue
The analysis of ALA and PBG was performed as described previ-
ously (van den Boogert et al, 1998). URO was extracted from 
25 ml tissue homogenate or plasma (two-fold diluted in NaCl 
(150 mmol l–1) by addition of 200 ml of URO extraction buffer
(UEB; Tris-HCl 50 mmol l–1, pH 8.0; trichloroacetic acid, 1.5 mol
l–1 in aqua dest., (3:5, v/v)). After 5 min exposure to UV light (350
nm), to convert porphyrinogens into porphyrins, the samples were
centrifuged for 7 min at 3000 g.
The fluorescence of the supernatant was measured at an excita-
tion wavelength of 410 nm and an emission wavelength of 656 nm
using a LS 50B spectrofluorometer with a red sensitive photomul-
tiplier (Perkin Elmer, Nieuwerkerk a/d ijssel, The Netherlands).
Values were calculated according to a standard curve of URO I in
UEB.
Recovery of porphyrins during the extraction was determined
by adding standard URO to the samples and in this study recov-
eries were found in the range of 85–100%. PPIX was extracted
from tissue by adding 50 ml PPIX extraction buffer (PEB; Tris-
HCl 50 mmol l–1, pH 8.0; 425 ml dimethylsulfoxide/methanol,
(DMSO/MeOH, 30:70, v/v)) to 25 ml tissue homogenate. The
diluted homogenate was mixed vigorously using a vortex and left
for about 30 min at room temperature. Samples were then
centrifuged for 10 min at 300 g. 100 ml of supernatant was injected
on a HPLC as described previously (van Hillegersberg et al, 1992),
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however using an excitation wavelength of 415 nm and an emis-
sion wavelength of 630 nm. For the extraction of PPIX from
plasma, 950 ml of PEB was added to 50 ml plasma. Values were
calculated according to standard curves of Zinc-PPIX and PPIX in
DMSO/MeOH (30:70, v/v). Recovery of porphyrins during the
extraction was determined by adding standard Zinc-PPIX and
PPIX to the samples and in this study recoveries were found in the
range of 90–100%. Plasma levels were expressed in nmol l–1 and
tissue levels in pmol mg–1 protein.
Protoporphyrin IX and its precursors
At 6 h after ALA administration, tissues not only contained PPIX
but also other haem synthesis intermediates, which are the precur-
sors of PPIX and therefore considered as potential PPIX. Since the
concentration of URO was very low in tissue and plasma samples
compared to PPIX, the URO data were omitted from further
analysis. PBG is formed from two molecules of ALA and four
molecules of PBG form a PPIX molecule. To calculate the poten-
tial PPIX molecules present at 6 h after ALA administration, the
concentrations of ALA and PBG were divided by 8 and 4 respec-
tively and we called this ‘PPIX equivalents’.
Statistical analysis
Data are expressed as means ± SEM and were tested for statistical
significance using Student’s t-test for paired values. Enzyme activ-
ities and concentrations of haem intermediates in BE, AC and GC
were compared to SQ. Pearson correlation coefficients were calcu-
lated to study possible correlations. P < 0.05 was considered
significant.
RESULTS
Porphobilinogen deaminase and ferrochelatase
activities and PDT power index
Before oral ALA administration, PBG-D and FC activities were
determined in endoscopically derived biopsy samples taken from
the oesophagus (BE, AC and SQ) and the proximal stomach (GC).
A two-fold increase in PBG-D activity (pmol per mg protein per
hr) was found in BE (39.18 ± 5.67, P = 0.013) and in AC (38.76 ±
3.98, P = 0.001) compared with SQ (19.72 ± 2.85), whereas the
activity in GC (21.46 ± 1.27) was not different from the activity in
SQ (Table 1). The activities of FC (pmol per mg protein per hr)
were not significantly different in BE (696 ± 89, P = 0.06) and AC
(532 ± 68, P = 0.36) compared to SQ (444 ± 49), whereas the FC
activity in GC (688 ± 38, P = 0.02) was significantly increased.
In BE, the PDT power index (1.4 ± 0.2, P = 0.18) was not
significantly different from SQ (1.0). In AC, this index was signif-
icantly increased (1.9 ± 0.3, P = 0.01) whereas in GC the index
was significantly decreased (0.7 ± 0.1, P = 0.01) compared to SQ.
Protoporphyrin IX and protoporphyrin equivalents
concentration in tissue
Tissue samples of nine patients were collected at a mean time interval
of 6.7 ± 0.5 h (range 5.25–10) after the administration of ALA. All
tissue types contained the same concentrations of ALA-PPIX equiv-
alents (Table 1). In BE, AC and GC, the intracellular concentration of
PBG-PPIX equivalents were significantly lower than in SQ.
The individual variability in the concentration of PPIX is
demonstrated in Table 2 together with the patients and tissues
characteristics. PPIX was the main metabolite of ALA found in
tissue. Undetectable low levels of porphyrins were found in tissue
samples of any of the nine patients when taken before the oral
administration of ALA (results not shown).
The concentration of PPIX in BE (77 ± 17) was not significantly
different from SQ (92 ± 15), whereas the concentration in GC was
significantly lower (57 ± 10, P = 0.01) (Table 1). Only one patient
(Table 1, patient 5) showed a selective accumulation of PPIX in
BE compared with SQ. Levels of PPIX did not depend on the
grade of dysplasia found in BE.
The concentration of PPIX in AC (112 ± 45) was not signifi-
cantly different from SQ (92 ± 15) (Table 1). Selective accumula-
tion of PPIX was seen in four cases of AC. Of the remaining four
cases of AC, in one patient tissue was obtained at 10 h after the
administration of ALA and in the other three cases the AC was
histologically found to be poorly differentiated.
The PDT power index did not correlate with the levels of PPIX
found.
Pharmacokinetics of 5-aminolaevulinic acid,
porphobilinogen and protoporphyrin IX in plasma
Plasma ALA, PBG, and PPIX kinetics are shown in Figure 2.
After the initial absorption and distribution phase the decrease in
ALA, PBG and PPIX followed first-order kinetics with half-lives
of 1.8, 5.9 and 6.7 h respectively. The range in the half-lives of
ALA, PBG and PPIX between different patients was considerable:
1.1–2.5 h for ALA, 4.1–11.6 h for PBG and 2.5–12.8 h for PPIX.
In all patients, peak concentrations of ALA were detected at 1 h
Table 1 Haem biosynthetic enzyme activities before ALA ingestion and the concentrations of PPIX and
‘PPIX equivalents’ (pmol per mg protein) at a mean time interval of 6.7 h after ALA ingestion (60 mg kg–1) in
gastro-oesophageal tissues of nine patients
‘PPIX ‘PPIX
Tissue equivalents’ equivalents’ PBG-D FC PDT power
type ALA/8 PBG/4 PPIX activity activity index
SQ 134 ± 38 312 ± 59 92 ± 15 20 ± 3 444 ± 49 1.0
BE 132 ± 39 201a ± 38 77 ± 17 39a ± 6 696 ± 89 1.4 ± 0.2
AC 101 ± 38 126a ± 30 112 ± 45 39a ± 4 532 ± 68 1.9a ± 0.3
GC 61 ± 19 129a ± 29 57a ± 10 21 ± 1 688a ± 38 0.7a ± 0.1
aP < 0.05 compared to SQ542 P Hinnen et al
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and concentrations declined to baseline levels at 24 h after admin-
istration. There was a considerable variability between patients in
the time to achieve the peak plasma concentrations of PBG and
PPIX (range: 6–12.3 h). Plasma concentrations of PBG and PPIX
declined to baseline levels at 48 h after ALA ingestion.
Side-effects
Side-effects were vomiting, skin photosensitivity, hypotension and
transient increases of ASAT and ALAT. Eight patients suffered
from at least one of these side-effects. Three patients vomited inci-
dentally between 2.5–4.5 h after the administration of ALA. ASAT
and ALAT were elevated 2–3-fold above normal levels in six
patients and peaked at day 2 after ALA administration. Mild skin
photosensitivity, characterized by itching and mild erythema was
present in seven patients. One patient had severe oedema of his
facial skin, lips and tongue. The symptoms improved sponta-
neously within 24 h. Hypotension was found in five patients, in
four patients intra-operatively, within 6 h after the administration
of ALA. The mean systolic blood pressure of these patients
dropped from 125–70 mmHg and the mean diastolic blood pres-
sure from 70–40 mmHg.
DISCUSSION
In patients with AC in BE we previously found increased activities
of PBG-D and FC in endoscopic biopsies of BE and AC compared
with SQ (Hinnen et al, 1998). Based on this observation we
proposed a PDT power index, the ratio between PBG-D and FC
activity in BE and AC in comparison with SQ. We suggested that
this index could be of value in predicting porphyrin concentrations
in these tissues after ALA administration.
Under the conditions chosen in the present study, however, the
PDT power index did not predict the level of intracellular PPIX
accumulation found at a mean time interval of 6.7 h after ALA
administration in BE, AC, SQ and GC in these patients. It is
possible that a relationship still exists between the PDT power
index and PPIX accumulation at another time-interval as we found
higher enzyme activities and lower PPIX precursor concentrations
in AC and BE compared to SQ (Table 1). It is therefore possible
that PPIX levels could have peaked at earlier time intervals in BE
and AC compared to SQ.
As found by others, who determined PPIX by fluorescence
microscopy, an indirect, semi-quantitative method (Regula et al,
1995; Barr et al, 1996), there seemed to be little selectivity of
PPIX accumulation in BE. In contrast, we found selective accumu-
lation of PPIX in four of eight cases of AC. The other four AC
samples contained only low levels of PPIX, as compared to SQ. In
Table 2 Patient and tissue characteristics of nine patients after the oral administration of 60 mg kg–1 ALA
Age Tumour Grade of Sampling PPIX PPIX PPIX PPIX
(yrs) Sex diff. grade dysplasia time (h) SQ BE AC GC
1 51 M moderately LGD 10 86 46 31 67
2 45 M moderately ND 5.25 55 55 82 60
3 79 F – HGD 6.16 172 173 125
4 73 M well LGD 6 51 40 78 36
5 69 M poorly ND 7.83 85 107 142 54
6 72 M poorly ND 6 80 84 60 44
7 77 F poorly ND 6.67 68 24 50 36
8 63 M poorly LGD 7.83 60 34 37 26
9 45 M moderately LGD 6 168 127 414 64
ND = no dysplasia; LGD = low-grade dysplasia; HGD = high-grade dysplasia; Sampling time = sampling time after ALA; PPIX
concentrations in pmol per mg protein. Data in bold, selective accumulation of PPIX compared to other tissue samples of the same
patient
0
1
10
10
100
1000
10000
100000
1000000
20 30 40 50
Plasma ALA concentration (nmol L—1)
Hours after ALA
t1/2 (h) 1.8 – 0.1
tmax (h) 1.0 – 0.0
Cmax (nmol L—1) 484 · 103
0
1
10
10
100
1000
10000
100000
20 30 40 50
Plasma PBG concentration (nmol L—1)
Hours after ALA
t1/2 (h) 5.9 – 0.8
tmax (h) 7.5 – 0.8
Cmax (nmol L—1)1 7 · 103
0
1
10
10
100
1000
10000
20 30 40 50
Plasma PPIX concentration (nmol L
—1)
Hours after ALA
t1/2 (h) 6.7 – 0.9
tmax (h) 9.4 – 0.7
Cmax(nmol L—1)1 · 103
Figure 2 Pharmacokinetics of ALA, PBG and PPIX in plasma of 10 patients
after ingestion of ALA (60 mg kg–1). The plasma concentrations are
expressed as log-values (y-axis, means ± SEM)Porphyrin biosynthesis in human oesophagus after ALA ingestion 543
British Journal of Cancer (2000) 83(4), 539–543 © 2000 Cancer Research Campaign
three of these cases the histology showed a poorly differentiated
tumour. It has been reported that the grade of differentiation can
have a negative or positive effect on the ability of cells to accumu-
late porphyrins, depending on the type of tissue (Li et al, 1999). In
the fourth patient without selectivity between AC and SQ, tissue
was collected at a rather late time (10 h) after the administration of
ALA, at which time PPIX could already have been converted into
haem.
Not only is the absolute intracellular PPIX concentration an
important factor for the effect of PDT but also the intracellular
localization of PPIX at the time of application of PDT, the duration
of illumination and the flux of PPIX in cells (Iinuma et al, 1994;
Hinnen et al, 2000b). If oxygen levels are high enough, more PPIX
molecules per time-unit result in a greater oxygen radical yield,
and therefore will have a more pronounced effect (Henderson and
Dougherty, 1992).
The rapid kinetics of ALA and PPIX found in plasma (Figure 2)
explain why ALA is an attractive pro-drug for PDT. PPIX in
plasma is derived from liver and other cells and the decline in
plasma levels reflects a decline in tissue levels (van den Boogert et
al, 1998). Because of this rapid decline in PPIX levels, skin photo-
sensitivity is only short-lasting (Barr et al, 1996; Gossner et al,
1998).
A severe side-effect observed in this study was hypotension.
Herman et al, recently studied the haemodynamic effects of ALA.
A relevant observation in that study was a significant decrease in
the systolic and diastolic blood pressure in all six patients (Herman
et al, 1998). Goldberg et al found in animal studies evidence for an
ALA-triggered histamine release, which could result in vasodilata-
tion and in that way hypotension (Goldberg and McGillion, 1973).
Based on these findings we treated four of our patients with anti-
histaminic agents and corticosteroids prior to ALA administration,
but this failed to prevent hypotension in all of them.
Haemodynamic stability was restored by infusion of isotonic
fluids and plasma. It is presently not clear whether ALA, PPIX or
a metabolite is responsible for this side-effect.
In conclusion, this study describes the photodynamic potential
of the haem biosynthetic pathway in tissues of patients with BE
and AC. At a mean time-interval of 6.7 h after ALA administra-
tion, PPIX accumulation could not be predicted from the PDT
power index. Selectivity of PPIX accumulation was found in half
of the cases of AC but not in BE. The optimum time interval is still
not established but is possibly found at an earlier time interval
after ALA administration. Side-effects after ingestion of 60 mg
kg–1 ALA can be serious and a hypotensive response can occur.
Optimizing the results of ALA-PDT in the treatment of BE and
AC requires further effort in studies concerning the kinetics of
ALA and its products in target tissues.
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